Cellebrite DI (CLBT) to Release Quarterly Earnings on Wednesday

Cellebrite DI (NASDAQ:CLBT) is expected to release its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $126.0740 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:30 AM ET.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.05). Cellebrite DI had a net margin of 16.74% and a return on equity of 20.81%. The firm had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. During the same period in the previous year, the company earned $0.14 earnings per share. Cellebrite DI’s revenue was up 17.9% on a year-over-year basis. On average, analysts expect Cellebrite DI to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellebrite DI Stock Performance

Shares of CLBT opened at $14.65 on Tuesday. The stock has a 50-day moving average of $17.35 and a two-hundred day moving average of $17.02. The stock has a market cap of $3.51 billion, a P/E ratio of 47.26, a P/E/G ratio of 1.98 and a beta of 1.28. Cellebrite DI has a one year low of $13.10 and a one year high of $25.87.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Advisory Services Network LLC acquired a new stake in shares of Cellebrite DI during the 3rd quarter valued at about $40,000. Vestcor Inc acquired a new stake in Cellebrite DI in the third quarter valued at approximately $70,000. Virtus Advisers LLC increased its position in shares of Cellebrite DI by 297.7% in the third quarter. Virtus Advisers LLC now owns 12,954 shares of the company’s stock valued at $240,000 after buying an additional 9,697 shares in the last quarter. Amundi purchased a new stake in shares of Cellebrite DI in the third quarter valued at approximately $264,000. Finally, First Trust Advisors LP acquired a new position in shares of Cellebrite DI during the 2nd quarter worth approximately $341,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on CLBT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Bank of America upped their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $24.00.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.